Investigational drug · Phase 3
HIP0612
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastric Ulcer.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "HIP0612"
First trial start
2023
Mar 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HIP0612", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Ulcer
Approved drugs for the same conditions: Stomach and esophageal cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "HIP0612" as an intervention, largest first.
- A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric UlcerPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT05656092 · 199 participants · Start Mar 6, 2023 · Primary completion Dec 19, 2024
Drug: HIP0612; HPP2202 and 2 more · For: Gastric Ulcer
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Gastric Ulcer
- DWP14012FexuprazanPhase 33 trials
Daewoong Pharmaceutical Co. LTD. · Healed Erosive Esophagitis, Gastric Ulcer, Helicobacter Pylori Infection
- HPP2201Phase 31 trial
Hanmi Pharmaceutical Company Limited · Gastric Ulcer
- HPP2202Phase 31 trial
Hanmi Pharmaceutical Company Limited · Gastric Ulcer
- RLD2204Phase 31 trial
Hanmi Pharmaceutical Company Limited · Gastric Ulcer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.